

EFFECTIVE DATE: 01|01|2024

POLICY LAST REVIEWED: 09|18|2024

OVERVIEW

Duchenne muscular dystrophy (DMD) is an inherited disorder that results in progressive muscle weakness and loss of muscle mass, primarily affecting males. DMD results from non-sense or frame-shifting variant(s) in the DMD gene which is responsible for producing dystrophin, a cohesive protein essential for maintaining muscle support and strength. Delandistrogene moxeparvovec-rokl is an adeno-associated virus vector-based gene therapy which encodes a novel, engineered protein micro-dystrophin protein. This novel micro-dystrophin protein is a shortened version (138 kDa, compared to 427 kDa size of dystrophin expressed in normal muscle cells) that contains selected domains of dystrophin expressed in normal muscle cells.

MEDICAL CRITERIA

Not applicable.

PRIOR AUTHORIZATION

Not applicable.

POLICY STATEMENT

The use of delandistrogene moxeparvovec-rokl is considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products for all indications including the treatment of Duchenne muscular dystrophy as the evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for not medically necessary/not covered pharmacy benefits/coverage.

BACKGROUND

Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is an X-linked, recessive disorder that occurs in approximately 1 in every 3500 to 5000 males. It primarily affects males. However, females are also affected, but are usually asymptomatic. Even when symptomatic, most females typically only present with a mild form of the disease. According to U.S. epidemiologic data, the first signs or symptoms of DMD are noted at a mean age of 2.5 years (range, 0.2 to 1 years). Although histologic and laboratory evidence of myopathy may be present at birth, the clinical onset of skeletal muscle weakness usually does not become evident until early childhood. The average age at diagnosis is approximately 5 years. Symptoms include motor difficulties such as difficulty running, jumping, and walking up stairs, along with an unusual waddling gait. Some improvement in symptoms may be seen from 3 to 6 years of age, though gradual deterioration resumes and most individuals lose ambulation by age 12 and require noninvasive ventilation by the late teenage years. Individuals progress from needing noninvasive ventilation only during night sleeping, followed by noninvasive ventilation during day and night sleeping, and then noninvasive ventilation during day and night over the course of 5 to 10 years. Median life expectancy more recently has increased into the fourth decade, primarily through improved respiratory management and cardiac care.

DMD occurs as a result of variant(s) in the gene responsible for producing dystrophin, a cohesive protein that is essential for maintaining muscle support and strength. DMD is the longest known human gene, and several variants can cause DMD. Most deletion variants disrupt the translational reading frame in the dystrophin messenger RNA resulting in an unstable, nonfunctional dystrophin molecule. As a result, there is

progressive muscle degeneration leading to loss of independent ambulation, as well as other complications, including respiratory and cardiac complications. Genetic testing is required to determine the specific DMD gene variant(s) for a definitive diagnosis, even when the absence of dystrophin protein expression has been confirmed by muscle biopsy. There are over 4700 variants in the Leiden DMD mutation database, and the most common variants are concentrated between exons 45 and 53.

Regulatory Status

In June 2023, delandistrogene moxeparovec-rokl (Elevidys; Sarepta Therapeutics) was approved by the U.S. Food and Drug Administration (FDA) for treatment of ambulatory pediatric patients aged 4 through 5 years with DMD with a confirmed mutation in the DMD gene. This indication was approved under accelerated approval based on expression of delandistrogene moxeparovec-rokl micro-dystrophin in skeletal muscle observed in patients treated with delandistrogene moxeparovec-rokl. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

In June 2024, the U.S. FDA expanded the approval of delandistrogene moxeparovec-rokl (Elevidys; Sarepta Therapeutics) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene. It received a traditional approval in ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene, and accelerated approval in non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.

Treatment with delandistrogene moxeparovec-rokl is intended to slow or stabilize progression of DMD, to alter the disease trajectory to a milder, Becker muscular dystrophy-like phenotype. Becker muscular dystrophy is ~~very~~ similar to DMD, except that in Becker, symptoms begin later and progress at a slower rate.

For individuals with a confirmed diagnosis of Duchenne muscular dystrophy (DMD) who receive delandistrogene moxeparovec-rokl, the evidence includes 2 randomized controlled trials (studies 102 and 301) and 1 prospective cohort trial (study 103). Relevant outcomes are disease-specific survival, change in disease status, functional outcomes, health status measures, quality of life, and treatment-related mortality and morbidity. In study 102, 41 study participants were randomized 1:1 to receive either delandistrogene moxeparovec-rokl (n=20) or placebo (n=21). In study 301, 125 study participants were randomized 1:1 to receive either delandistrogene moxeparovec-rokl (n=63) or placebo (n=62). Both studies failed to show a statistically significant difference in the primary endpoint of change in the North Star Ambulatory Assessment (NSAA) total score between the treated and the placebo group. In study 102, the least squares (LS) mean change in the NSAA total score from baseline to week 48 was 1.7 points for the delandistrogene moxeparovec-rokl group and 0.9 points for the placebo group (p=.37). In study 301, the LS mean change in the NSAA total score from baseline to week 52 was 2.57 points for the delandistrogene moxeparovec-rokl group and 1.92 points for the placebo group (p=.24). Thus, clinical benefit was not demonstrated in the primary efficacy endpoint of NSAA total score from baseline in both studies. Multiple limitations were noted. The US FDA approval was based on the post-hoc exploratory analysis of secondary outcome measures such as 10-meter walk/run (10-MWR) and time to rise from floor. These results cannot be interpreted at face value due to the lack of pre-specification and control of type 1 error. Such post hoc analysis following an overall nonsignificant test in the overall population can only be considered as hypothesis-generating. In addition, the observed treatment effect on secondary outcomes was not substantial and of uncertain clinical significance. Further, the results of 10-MWR timed test were inconsistent with opposing results observed in the 2 RCTs. Because of these limitations, an adequately powered, randomized, double-blind, placebo-controlled trial is necessary to clearly ascertain the net health outcome in DMD. Lastly, biomarker data reported in studies only provides information about expression of the transgene product in cells transduced by delandistrogene moxeparovec-rokl rather than insight into a pharmacologic effect on a known biomarker in the pathway of the disease. Delandistrogene moxeparovec-rokl micro-dystrophin is a novel, engineered protein that contains selected domains of the normal, wild-type dystrophin expressed in healthy muscle cells. No epidemiologic or pathophysiologic evidence is available regarding the function of delandistrogene moxeparovec-rokl micro-dystrophin. The protein differs in important ways from both the endogenous shortened forms of dystrophin in patients with Becker muscular dystrophy, and the internally truncated dystrophins expressed through exon-skipping drugs. Thus, the clinical benefit of treating DMD with

delandistrogene moxeparovec-rokl, including improved motor function and pulmonary function, has not been demonstrated. A confirmatory, prospective, and adequately powered trial is necessary to assess the net health outcome of delandistrogene moxeparovec-rokl in patients with DMD. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

CODING

The following HCPCS code(s) are considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products:

J1413 Elevidys (Sarepta Therapeutics, Inc.); Injection, delandistrogene moxeparovec-rokl, per therapeutic dose (New Code Effective 1/1/2024). Prior to Dates of Service 1/1/2024, Unlisted HCPCS code C9399 or J3590 must be used).

RELATED POLICIES

Not applicable.

PUBLISHED

Provider Update, February/November 2024

REFERENCES

1. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. *Lancet Neurol.* Feb 2010; 9(2): 177-89. PMID 19945914
2. Center for Disease Control and Prevention. Muscular Dystrophy: MD STARnet Data and Statistics. Available at <http://www.cdc.gov/ncbddd/muscular dystrophy/data.html>. Accessed July 7, 2024.
3. Falzarano MS, Scotton C, Passarelli C, et al. Duchenne Muscular Dystrophy: From Diagnosis to Therapy. *Molecules.* Oct 07 2015; 20(10): 18168-84. PMID 26457695
4. Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry. Published February 2018. Available at <https://www.fda.gov/media/92233/download>. Accessed July 7, 2024.
5. Zambon AA, Ayyar Gupta V, Ridout D, et al. Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy. *Dev Med Child Neurol.* Aug 2022; 64(8): 979-988. PMID 35385138
6. McDonald CM, Henricson EK, Abresch RT, et al. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. *Muscle Nerve.* Sep 2013; 48(3): 343-56. PMID 23681930
7. Henricson E, Abresch R, Han JJ, et al. The 6-Minute Walk Test and Person-Reported Outcomes in Boys with Duchenne Muscular Dystrophy and Typically Developing Controls: Longitudinal Comparisons and Clinically-Meaningful Changes Over One Year. *PLoS Curr.* Jul 08 2013; 5. PMID 23867975
8. Food and Drug Administration. Statistical Reviewer: Thomas Zhou. STN: 125781/34. Available at <https://www.fda.gov/media/179489/download?attachment>. Accessed July 24, 2024.
9. Food and Drug Administration. Center Director Decisional Memo for BLA 125781//AMENDMENT 34; Elevidys (delandistrogene moxeparovec-rokl). Available at <https://www.fda.gov/media/179485/download>. Accessed July 24, 2024.
10. Food and Drug Administration. Center Director Decisional Memo for BLA 125781; Elevidys (delandistrogene moxeparovec-rokl). Available at <https://www.fda.gov/media/169707/download>. Accessed July 5, 2024.
11. Mendell JR, Sahenk Z, Lehman K, et al. Assessment of Systemic Delivery of rAAVrh74.MHCK7.microdystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial. *JAMA Neurol.* Sep 01 2020; 77(9): 1122-1131. PMID 32539076
12. Mendell JR, Sahenk Z, Lehman KJ, et al. Long-term safety and functional outcomes of delandistrogene moxeparovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial. *Muscle Nerve.* Jan 2024; 69(1): 93-98. PMID 37577753
13. Mendell JR, Shieh PB, McDonald CM, et al. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparovec gene therapy in individuals with Duchenne muscular dystrophy. *Front Cell Dev Biol.* 2023; 11: 1167762. PMID 37497476

14. Zaidman CM, Proud CM, McDonald CM, et al. Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥ 4 to 8 Years) with Duchenne Muscular Dystrophy: 1-Year Interim Results from Study SRP-9001-103(ENDEAVOR). *Ann Neurol*. Nov 2023; 94(5): 955-968. PMID 37539981
15. Prescribing Label: Elevidys (delandistrogene moxeparvovec-rokl) suspension, for intravenous infusion. Available at <https://www.fda.gov/media/169679/download>. Accessed on July 5, 2023.
16. Food and Drug Administration. Sponsor Briefing Document for SRP-9001 (delandistrogene moxeparvovec) for the treatment of duchenne muscular dystrophy. Cellular, Tissue, and Gene Therapies Advisory Committee. Meeting date 12 May 2023. Available at <https://www.fda.gov/media/168022/download>. Accessed July 12, 2024.
17. Gloss D, Moxley RT, Ashwal S, et al. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. Feb 02 2016; 86(5): 465-72. PMID 26833937
18. Feingold B, Mahle WT, Auerbach S, et al. Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. *Circulation*. Sep 26 2017; 136(13): e200-e231. PMID 28838934
19. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. *Lancet Neurol*. Mar 2018; 17(3): 251-267. PMID 29395989
20. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. *Lancet Neurol*. Apr 2018; 17(4): 347-361. PMID 29395990

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

